Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy

NCT00382031 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT00382031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00382031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Labeled Randomized Parallel Group Trial of Zalutumumab, a Human Monoclonal Anti-EGFr Antibody, in Combination With Best Supportive Care (BSC) vs BSC, in Pts With Non-Curable SCCHN Who Have Failed Standard Platinum-Based Chemotherapy
Lead sponsor
Genmab
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
August 31, 2011
Enrollment
286 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, squamous cell cancer